Pharmafile Logo

Elecsys

- PMLiVE

AL-S Pharma release new data from AP-101 phase 2 trial for ALS

ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord

- PMLiVE

Roche opens new Swiss Institute of Human Biology research facility

The new building is part of a 1.5bn euro site investment

- PMLiVE

Roche’s Columvi improves survival in large B-cell lymphoma

Approximately 160,000 people are diagnosed with this aggressive form of cancer each year

- PMLiVE

Roche receives FDA clearance for whooping cough test

There are around 24.1 million cases of whooping cough annually, with around 170,000 deaths

- PMLiVE

Genentech announces positive clinical results for BTK inhibitor MS treatment

Multiple sclerosis affects more than 2.9 million people globally

- PMLiVE

Lilly and WHO Foundation partner to support global dementia action plan

The partnership will provide financial support and strengthen early detection and intervention efforts

- PMLiVE

Roche’s small cell lung cancer therapy approved by FDA

This is the first and only approved combination therapy for extensive-stage small cell lung cancer

- PMLiVE

Roche’s Lunsumio receives positive CHMP opinion for follicular lymphoma

The recommendation for the subcutaneous formulation follows encouraging trial data

- PMLiVE

Roche to acquire 89bio in a deal worth up to US$3.5bn

With the agreement, Roche will gain a treatment for moderate to severe MASH

- PMLiVE

TRIMTECH Therapeutics establishes Scientific Advisory Board

Alessio Ciulli has been appointed as Chair of the board

- PMLiVE

Genentech starts construction on manufacturing facility in North Carolina, US

The $700m project is part of Roche’s $50bn investment in the US

- PMLiVE

Eli Lilly’s Alzheimer’s drug Kisunla shows growing benefit in long-term study

More than seven million people in the US are affected by the neurodegenerative disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links